تقرير
أعرض في EDS

Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.

التفاصيل البيبلوغرافية
العنوان: Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
المؤلفون: Gounari M; Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.; Division of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy., Ntoufa S; Institute of Applied Biosciences, CERTH, Thessaloniki, Greece., Gerousi M; Institute of Applied Biosciences, CERTH, Thessaloniki, Greece., Vilia MG; Division of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy., Moysiadis T; Institute of Applied Biosciences, CERTH, Thessaloniki, Greece., Kotta K; Institute of Applied Biosciences, CERTH, Thessaloniki, Greece., Papakonstantinou N; Institute of Applied Biosciences, CERTH, Thessaloniki, Greece., Scarfò L; Division of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy., Agathangelidis A; Institute of Applied Biosciences, CERTH, Thessaloniki, Greece., Fonte E; Division of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy., Ranghetti P; Division of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy., Nenou A; Institute of Applied Biosciences, CERTH, Thessaloniki, Greece., Xochelli A; Institute of Applied Biosciences, CERTH, Thessaloniki, Greece., Coscia M; Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliero Universitaria S. Giovanni Battista di Torino, Torino, Italy., Tedeschi A; Department of Oncology/Haematology, Niguarda Cancer Center, Niguarda Ca Granda Hospital, Milan, Italy., Stavroyianni N; Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece., Muzio M; Division of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy., Stamatopoulos K; Institute of Applied Biosciences, CERTH, Thessaloniki, Greece. kostas.stamatopoulos@gmail.com.; Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden. kostas.stamatopoulos@gmail.com., Ghia P; Division of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.
المصدر: Leukemia [Leukemia] 2019 Apr; Vol. 33 (4), pp. 1030-1051. Date of Electronic Publication: 2019 Jan 03.
نوع المنشور: Letter; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia
أسماء مطبوعة: Publication: 2000- : London : Nature Publishing Group, Specialist Journals
Original Publication: [Baltimore, Md.] : Williams & Wilkins, [c1987-
مواضيع طبية MeSH: Gene Expression Regulation, Neoplastic/*drug effects , Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy , Pyrazoles/*pharmacology , Pyrimidines/*pharmacology , Toll-Like Receptors/*metabolism, Adenine/analogs & derivatives ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Piperidines ; Prognosis
References: Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–37. (PMID: 10.1056/NEJMoa1509388)
Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–94. (PMID: 10.1056/NEJMoa1400029)
Brunner C, Muller B, Wirth T. Bruton’s tyrosine kinase is involved in innate and adaptive immunity. Histol Histopathol. 2005;20:945–55. (PMID: 15944945)
Kenny EF, Quinn SR, Doyle SL, Vink PM, van Eenennaam H, O'Neill LA. Bruton’s tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin. PLoS ONE. 2013;8:e74103. (PMID: 10.1371/journal.pone.0074103)
Ntoufa S, Vardi A, Papakonstantinou N, Anagnostopoulos A, Aleporou-Marinou V, Belessi C, et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med. 2012;18:1281–91. (PMID: 10.2119/molmed.2011.00480)
Kurosaki T, Tsukada S. BLNK: connecting Syk and Btk to calcium signals. Immunity. 2000;12:1–5. (PMID: 10.1016/S1074-7613(00)80153-3)
Ntoufa S, Papakonstantinou N, Apollonio B, Gounari M, Galigalidou C, Fonte E, et al. B cell anergy modulated by TLR1/2 and the miR-17 approximately 92 cluster underlies the indolent clinical course of chronic lymphocytic leukemia stereotyped subset #4. J Immunol. 2016;196:4410–7. (PMID: 10.4049/jimmunol.1502297)
Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123:3286–95. (PMID: 10.1182/blood-2014-02-548610)
Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810–7. (PMID: 10.1182/blood-2013-09-527853)
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182–9. (PMID: 10.1182/blood-2011-10-386417)
Khan WN, Alt FW, Gerstein RM, Malynn BA, Larsson I, Rathbun G, et al. Defective B cell development and function in Btk-deficient mice. Immunity. 1995;3:283–99. (PMID: 10.1016/1074-7613(95)90114-0)
Zorn CN, Keck S, Hendriks RW, Leitges M, Freudenberg MA, Huber M. Bruton’s tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells. Cell Signal. 2009;21:79–86. (PMID: 10.1016/j.cellsig.2008.09.010)
Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1:933–46. (PMID: 290343645637393)
Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK, Levy R. Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. Blood. 2015;125:2079–86. (PMID: 10.1182/blood-2014-08-593137)
Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014;370:2352–4. (PMID: 10.1056/NEJMc1402716)
المشرفين على المادة: 0 (Piperidines)
0 (Pyrazoles)
0 (Pyrimidines)
0 (Toll-Like Receptors)
1X70OSD4VX (ibrutinib)
JAC85A2161 (Adenine)
تواريخ الأحداث: Date Created: 20190105 Date Completed: 20190809 Latest Revision: 20220420
رمز التحديث: 20240628
DOI: 10.1038/s41375-018-0335-2
PMID: 30607020
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5551
DOI:10.1038/s41375-018-0335-2